Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory CLL and SLL Portfolio News / Karina Tin January 16, 2024 Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory CLL and SLL Read More »
Plexium Announces Appointment of Michael Martin, Ph.D. as President and CEO Portfolio News / Karina Tin January 15, 2024 Plexium Announces Appointment of Michael Martin, Ph.D. as President and CEO Read More »
NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need Portfolio News / Karina Tin January 9, 2024 NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need Read More »
Eikon Therapeutics to Provide Corporate Updates at the 42nd Annual J.P. Morgan Healthcare Conference Portfolio News / Karina Tin January 8, 2024 Eikon Therapeutics to Provide Corporate Updates at the 42nd Annual J.P. Morgan Healthcare Conference Read More »
ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones Portfolio News / Karina Tin January 8, 2024 ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones Read More »
Nurix Therapeutics Outlines 2024 Strategic Priorities with Advancement of Targeted Protein Modulation Pipeline in Cancer and Autoimmune Diseases Portfolio News / Karina Tin January 8, 2024 Nurix Therapeutics Outlines 2024 Strategic Priorities with Advancement of Targeted Protein Modulation Pipeline in Cancer and Autoimmune Diseases Read More »
Remix Therapeutics™ Closes $60 Million Financing to Advance REM-422, Pipeline of Small Molecule Therapies Designed to Reprogram RNA Processing to Treat Disease Portfolio News / Karina Tin January 3, 2024 Remix Therapeutics™ Closes $60 Million Financing to Advance REM-422, Pipeline of Small Molecule Therapies Designed to Reprogram RNA Processing to Treat Disease Read More »
Remix Therapeutics™ Enters Collaboration with Roche for the Discovery and Development of Small Molecule Therapeutics Modulating RNA Processing Portfolio News / Karina Tin January 3, 2024 Remix Therapeutics™ Enters Collaboration with Roche for the Discovery and Development of Small Molecule Therapeutics Modulating RNA Processing Read More »
Kimia Therapeutics Raises $55 Million Series A Portfolio News / Karina Tin December 19, 2023 Kimia Therapeutics Raises $55 Million Series A Read More »
Atavistik Bio Raises Additional $40 Million to Advance Precision Allosteric Small Molecule Therapeutics Portfolio News / Karina Tin December 19, 2023 Atavistik Bio Raises Additional $40 Million to Advance Precision Allosteric Small Molecule Therapeutics Read More »